Submitted:
11 April 2024
Posted:
12 April 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Material and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Declaration of Generative AI and AI-Assisted Technologies in the Writing Process
Conflicts of Interest
References
- Montanez A: Ruskin JN, Hebert PR, Lamas GA, Hennekens CH. Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies. Arch Intern Med 2004;164:943–8. [CrossRef]
- Arnold JM, Fitchett DH, Howlett JG, Lonn EM, Tardif J-C. Resting heart rate: a modifiable prognostic indicator of cardiovascular risk and outcomes? Can J Cardiol 2008;24 Suppl A:3A-8A. [CrossRef]
- Nielsen JB, Graff C, Rasmussen PV, Pietersen A, Lind B, Olesen MS, et al. Risk prediction of cardiovascular death based on the QTc interval: evaluating age and gender differences in a large primary care population. Eur Heart J 2014;35:1335–44. [CrossRef]
- Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999;99:529–33. [CrossRef]
- Vink AS, Clur S-AB, Wilde AAM, Blom NA. Effect of age and gender on the QTc-interval in healthy individuals and patients with long-QT syndrome. Trends Cardiovasc Med 2018;28:64–75. [CrossRef]
- Mehta AJ, Kloog I, Zanobetti A, Coull BA, Sparrow D, Vokonas P, et al. Associations between Changes in City and Address Specific Temperature and QT Interval - The VA Normative Aging Study. PLoS ONE 2014;9:e106258. [CrossRef]
- Al-Khatib SM, LaPointe NMA, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA 2003;289:2120–7. [CrossRef]
- El-Sherif N, Turitto G. Electrolyte disorders and arrhythmogenesis. Cardiol J 2011;18:233–45. [CrossRef]
- Shah SR, Park K, Alweis R. Long QT Syndrome: A Comprehensive Review of the Literature and Current Evidence. Curr Probl Cardiol 2019;44:92–106. [CrossRef]
- Malik M. Problems of Heart Rate Correction in Assessment of Drug-Induced QT Interval Prolongation. J Cardiovasc Electrophysiol 2001;12:411–20. [CrossRef]
- Strohmer B, Schernthanere C, Paulweber B, Pichler M. Gender-specific comparison of five QT correction formulae in middle-aged participants in an atherosclerosis prevention program. Med Sci Monit Int Med J Exp Clin Res 2007;13:CR165-171.
- Rogowski O, Shapira I, Shirom A, Melamed S, Toker S, Berliner S. Heart rate and microinflammation in men: a relevant atherothrombotic link. Heart 2007;93:940–4. [CrossRef]
- Larsen A-I. The pulse; from adagio to prestissimo; the prognostic importance of heart rate increase and its associations with cardiovascular risk factors. Eur J Prev Cardiol 2020;27:520–5. [CrossRef]
- Hermansen R, Jacobsen BK, Løchen M-L, Morseth B. Leisure time and occupational physical activity, resting heart rate and mortality in the Arctic region of Norway: The Finnmark Study. Eur J Prev Cardiol 2019;26:1636–44. [CrossRef]
- Jensen MT, Suadicani P, Hein HO, Gyntelberg F. Elevated resting heart rate, physical fitness and all-cause mortality: a 16-year follow-up in the Copenhagen Male Study. Heart Br Card Soc 2013;99:882–7. [CrossRef]
- Chiladakis J, Kalogeropoulos A, Arvanitis P, Koutsogiannis N, Zagli F, Alexopoulos D. Heart rate-dependence of QTc intervals assessed by different correction methods in patients with normal or prolonged repolarization. Pacing Clin Electrophysiol PACE 2010;33:553–60. [CrossRef]
- Vandenberk B, Vandael E, Robyns T, Vandenberghe J, Garweg C, Foulon V, et al. Which QT Correction Formulae to Use for QT Monitoring? J Am Heart Assoc 2016;5:e003264. [CrossRef]
- Desai M, Li L, Desta Z, Malik M, Flockhart D. Variability of heart rate correction methods for the QT interval. Br J Clin Pharmacol 2003;55:511–7. [CrossRef]
- Malik M. The imprecision in heart rate correction may lead to artificial observations of drug induced QT interval changes. Pacing Clin Electrophysiol PACE 2002;25:209–16. [CrossRef]
- Noseworthy PA, Peloso GM, Hwang S-J, Larson MG, Levy D, O’Donnell CJ, et al. QT interval and long-term mortality risk in the Framingham Heart Study. Ann Noninvasive Electrocardiol Off J Int Soc Holter Noninvasive Electrocardiol Inc 2012;17:340–8. [CrossRef]
- Yazdanpanah MH, Naghizadeh MM, Sayyadipoor S, Farjam M. The best QT correction formula in a non-hospitalized population: the Fasa PERSIAN cohort study. BMC Cardiovasc Disord 2022;22:52. [CrossRef]
- Giovanardi P, Vernia C, Tincani E, Giberti C, Silipo F, Fabbo A. Combined Effects of Age and Comorbidities on Electrocardiographic Parameters in a Large Non-Selected Population. J Clin Med 2022;11:3737. [CrossRef]
- Rautaharju PM, Surawicz B, Gettes LS. AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram. Circulation 2009;119:e241–50. [CrossRef]
- Palatini P, Benetos A, Grassi G, Julius S, Kjeldsen SE, Mancia G, et al. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens 2006;24:603–10. [CrossRef]
- Zhang D, Shen X, Qi X. Resting heart rate and all-cause and cardiovascular mortality in the general population: a meta-analysis. CMAJ Can Med Assoc J J Assoc Medicale Can 2016;188:E53–63. [CrossRef]
- Ristow B, Doubell A, Derman W, Heine M. Change in resting heart rate and risk for all-cause mortality. Eur J Prev Cardiol 2022;29:e249–54. [CrossRef]
- Aune D, Sen A, ó’Hartaigh B, Janszky I, Romundstad PR, Tonstad S, et al. Resting heart rate and the risk of cardiovascular disease, total cancer, and all-cause mortality - A systematic review and dose-response meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis NMCD 2017;27:504–17. [CrossRef]
- Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987–1003. [CrossRef]
- Chen X, Barywani SB, Hansson P-O, Thunström EÖ, Rosengren A, Ergatoudes C, et al. Impact of changes in heart rate with age on all-cause death and cardiovascular events in 50-year-old men from the general population. Open Heart 2019;6:e000856. [CrossRef]



| Clinical and ECG characteristics of the whole population | Clinical and ECG characteristics of the 3 facilities | ||||
| Enrolled patients§ | 131627 | Emergency department group§ | 29010 | p <0.001 | |
| Men§ 64386 (48.9%) | Women§ 67241 (51.1%) | p <0.001 | Men§ 14658 (50.5%) Women§ 14352 (49.5%) |
||
| Mean enrollment age (years)* | 57.5 ± 16 | QTc Bazett° | 435.8 ± 28.2* | ||
| Men* 58.3 +/- 15.3 | Women* 56.8 +/- 16.6 | p <0.001 | QTc Fridericia° | 423.1 ± 26.6* | |
| Aall-cause mortality§ | 11727 (8.9%) | QTc Framingham° | 420.4 ± 24.5* | ||
| Men§ 6370 (54.3%) | Women§ 5357 (45.7%) | p <0.001 | HR^ | 76.6 ± 16.4* | |
| Mean Heart Rate^ | 72.6 ± 14.3 | Surgical/Medical Units group§ | 85604 | ||
| Men^ 70.8 ± 14.4 | Women^ 74.3 ± 13 | p <0.001 | Men§ 42141 (49.2%) Women§ 43463 (50.8%) |
||
| QRS duration° | 89.3 ± 13 | QTc Bazett° | 429.6 ± 28.4* | ||
| Men° 94.1 ± 13.2 | Women° 84.7 ± 10.9 | p <0.001 | QTc Fridericia° | 420.7 ± 25.9* | |
| T duration° | 189.7 ± 39.6 | QTc Framingham° | 418.6 ± 24* | ||
| Men° 186.3 ± 34.8 | Women° 192.9 ± 43.4 | p <0.001 | HR^ | 71.9 ± 13.6* | |
| QTc interval Bazett° | 429.1 ± 28.1 | Ambulatory group§ | 17013 | ||
| Men° 425.7 ± 28.8 | Women° 433 ± 26.7 | p <0.001 | Men§ 7587 (44.6%) Women§ 9426 (55.4%) |
||
| QTc interval Fridericia° | 420.2 ± 25.5 | QTc Bazett° | 421.6 ± 23.3* | ||
| Men° 417 ± 25.7 | Women° 422.8 ± 24.9 | p <0.001 | QTc Fridericia° | 413.3 ± 19.6* | |
| QTc interval Framingham° | 418.4 ± 23.6 | QTc Framingham° | 413.9 ± 19.2* | ||
| Men° 415 ± 24.1 | Women° 420.7 ± 22.9 | p <0.001 | HR^ | 69.0 ± 11.7* | |
| Exclusion criteria (excluded patients 243580) | |||||
| Incorrect and Bad signals qualities ECG§ | 14087 | atrial tachycardias and tachiarrythmias§ | 21358 | ||
| Young and very old people§ | 46378 | Bundle branch block§ | 25145 | ||
| Multiple ECG§ | 118595 | Second and third-degree AV block§ | 1768 | ||
| Pacemaker, implantable defibrillator§ | 4748 | Others§ | 11501 | ||
| Comparison | Mean difference (msec) | 95% CI° | p |
| QTc Bazett vs. QTc Fridericia | 9.71 | [9.66, 9.78] | < 0.001 |
| QTc Bazett vs. QTc Framingham | 11.54 | [11.46, 11.62] | < 0.001 |
| QTc Fridericia vs. QTc Framingham | 1.825 | [1.78, 1.87] | < 0.001 |
| Linear regression QTc vs. RR* interval | |||
| slope | 95% CI° | R2 | |
| QTc Bazett | -0.077 | [-0.078, -0.076] | 0.198 |
| QTc Fridericia | -0.086 | [-0.094, -0.008] | 0.003 |
| QTc Framingham | 0.0052 | [0.004, 0.006] | 0.001 |
| Whole population: 131627 patients | |||||||||
| Median |
25th percentile |
75th percentile |
25th percentile mortality (%) |
75th percentile mortality (%) |
B | p | Exp (B)* | 95% CI” | |
| QTc Bazett° | 428 | 412 | 446 | 9.55 | 20.3 | 0.927 | < 0.001 | 2.527 | [2.447, 2.61] |
| QTc Fridericia° | 418 | 404 | 434 | 7.14 | 9.5 | 0.798 | < 0.001 | 2.221 | [2.15, 2.294] |
| QTc Framingham° | 416 | 404 | 431 | 7.6 | 9.46 | 0.788 | < 0.001 | 2.198 | [2.128, 2.271] |
| HR^ | 71 | 63 | 81 | 8.65 | 16.72 | 0.607 | < 0.001 | 1.835 | [1.775, 1.897] |
| Group 1 (25-45 years): 33849 patients | |||||||||
| Median |
25th percentile |
75th percentile |
25th percentile mortality (%) |
75th percentile mortality (%) |
B | p | Exp (B)* | 95% CI” | |
| QTc Bazett° | 422 | 406 | 438 | 0.45 | 1.71 | 0.817 | < 0.001 | 2.263 | [1.822, 2.811] |
| QTc Fridericia° | 410 | 397 | 424 | 0.73 | 1.43 | 0.481 | < 0.001 | 1.618 | [1.296, 2.022] |
| QTc Framingham° | 409 | 397 | 421 | 0.73 | 1.36 | 0.424 | < 0.001 | 1.528 | [1.22, 1.913] |
| HR^ | 72 | 64 | 82 | 0.65 | 1.71 | 0.880 | < 0.001 | 2.411 | [1.944, 2.992] |
| Group 2 (46-65 years): 50284 patients | |||||||||
| Median |
25th percentile |
75th percentile |
25th percentile mortality (%) |
75th percentile mortality (%) |
B | p | Exp (B)* | 95% CI” | |
| QTc Bazett° | 427 | 411 | 443 | 3.18 | 9.49 | 0.744 | < 0.001 | 2.105 | [1.955, 2.266] |
| QTc Fridericia° | 417 | 404 | 432 | 4.84 | 8.6 | 0.054 | < 0.001 | 1.716 | [1.591, 1.85] |
| QTc Framingham° | 416 | 404 | 429 | 5.33 | 7.91 | 0.434 | < 0.001 | 1.543 | [1.43, 1.665] |
| HR^ | 70 | 62 | 79 | 3.77 | 10.07 | 0.905 | < 0.001 | 2.472 | [2.297, 2.659] |
| Group 3 (66-85 years): 47494 patients | |||||||||
| Median |
25th percentile |
75th percentile |
25th percentile mortality (%) |
75th percentile mortality (%) |
B | p | Exp (B)* | 95% CI” | |
| QTc Bazett° | 435 | 418 | 454 | 16.69 | 35.54 | 0.618 | < 0.001 | 1.855 | [1.787, 1.926] |
| QTc Fridericia° | 425 | 410 | 442 | 20.40 | 33.58 | 0.472 | < 0.001 | 1.603 | [1.544, 1.666] |
| QTc Framingham° | 423 | 409 | 439 | 21.44 | 32.88 | 0.438 | < 0.001 | 1.550 | [1.492, 1.611] |
| HR^ | 70 | 62 | 80 | 18.76 | 34.37 | 0.607 | < 0.001 | 1.835 | [1.768, 1.905] |
| Whole population | ||||
|
Cox B |
Cox Exp (B) |
Cox 95% CI |
Cox p |
|
| QTc Bazett° | 0.400 | 1.492 | [1.423, 1.564] | <0.001 |
| QTc Fridericia° | 0.166 | 1.181 | [1.114, 1.252] | <0.001 |
| QTc Framingham° | 0.447 | 1.564 | [1.473, 1.661] | <0.001 |
| HR^ | 0.519 | 1.681 | [1.619, 1.745] | <0.001 |
| Group 1 (25-45 years) | ||||
|
Cox B |
Cox Exp (B) |
Cox 95% CI |
Cox p |
|
| QTc Bazett° | 0.412 | 1.510 | [1.107, 2.059] | 0.009 |
| QTc Fridericia° | 0.019 | 1.019 | [0.718, 1.446] | 0.917 |
| QTc Framingham° | 0.201 | 1.222 | [0.849, 1.761] | 0.280 |
| HR^ | 0.729 | 2.072 | [1.613, 2.662] | <0.001 |
| Group 2 (46-65 years) | ||||
|
Cox B |
Cox Exp (B) |
Cox 95% CI |
Cox p |
|
| QTc Bazett° | 0.258 | 1.295 | [1.164, 1.441] | <0.001 |
| QTc Fridericia° | 0.184 | 1.202 | [1.057, 1.366] | 0.005 |
| QTc Framingham° | 0.166 | 1.180 | [1.034, 1.348] | 0.014 |
| HR^ | 0.813 | 2.254 | [2.076, 2.449] | <0.001 |
| Group 3 (66-85 years) | ||||
|
Cox B |
Cox Exp (B) |
Cox 95% CI |
Cox p |
|
| QTc Bazett° | 0.259 | 1.296 | [1.226, 1.369] | <0.001 |
| QTc Fridericia° | 0.069 | 1.071 | [0.996, 1.153] | 0.065 |
| QTc Framingham° | 0.269 | 1.309 | [1.215, 1.410] | <0.001 |
| HR^ | 0.564 | 1.757 | [1.686, 1.831] | <0.001 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).